CN Stock MarketDetailed Quotes

688062 Mabwell

Watchlist
  • 19.20
  • -0.70-3.52%
Market Closed Jan 3 15:00 CST
7.67BMarket Cap-7.14P/E (TTM)

About Mabwell Company

The company is an innovative biopharmaceutical company with a full industrial chain layout. It always adheres to the vision of “turning innovation from dream to reality”, carries out the mission of “exploring life and benefiting health”. Through innovation at the source, the company provides patients with bioinnovative drugs with better curative efficacy and greater accessibility to meet unmet global clinical needs. The company's main business is R&D, production and sales of innovative drugs and biosimilar drugs. It is supported by efficient innovative research and development and industrialization capabilities, and obtains commercial profits through marketing and sales of therapeutic biological products. The main products are drugs such as antibodies, ADC drugs, recombinant proteins, and small molecule chemicals. Company honors: “Outstanding Case Award” for Shanghai Industrial Talent Team Building Work, “Approved Employer” by the Australian Institute of Accountants, Xingyao List “2021 China Bioinnovative Drug Most Growing Annual Award”, China Pharmaceutical Talent Brand List and the Most Competitive Brand.

Company Profile

Short Name-A迈威生物
Company NameMabwell (Shanghai) Bioscience Co., Ltd.
Listing DateJan 18, 2022
Issue Price34.80
Shares Offered99.90M share(s)
FoundedMay 12, 2017
Chairmandatao liu
Legal Representativedatao liu
General Managerdatao liu
Secretaryhuiguo hu
Employees1402
ProvinceShang Hai Shi
Phone021-58332260
Office AddressRoom 105, Building 2, No. 230 Cailun Road, China (Shanghai) Pilot Free Trade Zone
Zip Code201210
Registered AddressRoom 105, Building 2, No. 230 Cailun Road, China (Shanghai) Pilot Free Trade Zone
Fax021-58585793-6520
Emailir@mabwell.com
Business License91310115MA1K3Q5R7K
BusinessThe issuer is an innovative biopharmaceutical company. Its main business is R&D, production and sales of therapeutic biological products. The main products are antibody drugs. The issuer adheres to a research and development and commercialization strategy based on rapid follow-up and similar pioneering, complemented by biosimilar drugs that are urgently needed clinically.

Company Executives

  • Name
  • Position
  • Salary
  • datao liu
  • Directors, General Manager, Core Technical Personnel
  • 2.41M
  • yufeng wu
  • Directors
  • --
  • chunshan tang
  • Directors
  • --
  • xun gui
  • Directors
  • 1.36M
  • huiguo hu
  • Directors, Board Secretary, Deputy General Manager, Core Technical Personnel
  • 1.58M
  • fang wang
  • Independent Directors
  • --
  • zhengyu qin
  • Independent Directors, Chairman of the Audit Committee
  • --
  • qing xu
  • Independent Directors
  • 180.00K
  • qian zhao
  • Independent Directors
  • 180.00K
  • hefei wang
  • Securities Affairs Representative
  • --
  • jian chu
  • Chairman of the Supervisory Board, Auditors
  • --
  • yue yin
  • Auditors
  • 736.80K
  • hua ni
  • Deputy General Manager
  • 1.42M
  • jun hua
  • Deputy General Manager, Chief Financial Officer
  • 1.59M
  • han li
  • Deputy General Manager
  • 1.94M
  • shuhai wang
  • Deputy General Manager, Core Technical Personnel
  • 1.58M
  • xi chen
  • Deputy General Manager
  • 1.58M
  • hai wu
  • Core Technical Personnel
  • --
  • xin du
  • Core Technical Personnel
  • 3.14M
  • yinhan guo
  • Core Technical Personnel
  • 1.93M
  • junhui liang
  • Authorized Representative, Joint Company Secretary
  • --
  • xianghong huang
  • Employee Supervisors
  • 609.20K